Trial Profile
A Phase 1, First-In-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacokinetics of AMG 820 in Adult Subjects With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Jan 2023
Price :
$35
*
At a glance
- Drugs AMB 051 (Primary)
- Indications Colorectal cancer; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
- Sponsors Amgen
- 27 Jun 2017 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
- 20 Apr 2016 Results assessing safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of AMG 820 presented at the 107th Annual Meeting of the American Association for Cancer Research
- 14 Jan 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.